Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Proof-of-Concept Study Evaluating the Administration of Pegloticase (Krystexxa) with the Immunomodulator Methotrexate to Improve the Durability of KRYSTEXXA Response in Patients with Refractory Gouty Arthropathy

Trial Profile

A Prospective, Proof-of-Concept Study Evaluating the Administration of Pegloticase (Krystexxa) with the Immunomodulator Methotrexate to Improve the Durability of KRYSTEXXA Response in Patients with Refractory Gouty Arthropathy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methotrexate (Primary) ; Pegloticase (Primary) ; Folic acid
  • Indications Gout
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
    • 29 Nov 2018 New trial record
    • 24 Oct 2018 Results (n=8) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top